myotubularin related protein 12Genealiases: 3-PAP · PIP3AP
Q-omics provides the consensus-scored MTMR12 profile across patient tissues and cancer cell-line models. MTMR12 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, MTMR12 is differentially expressed in 11, with the highest sampling consensus in LIHC. Additionally, MTMR12 protein abundance shows 23,922 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, LIHC, and GBM as cancer lineages where MTMR12 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MTMR12 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MTMR12 survival associations across molecular data types. MTMR12 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (3) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MTMR12 RNA expression–survival associations across cancer types. High MTMR12 expression shows unfavorable associations in BLCA, but favorable associations in KIRC, HNSC, SKCM, ESCA and UCS. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for MTMR12 RNA expression.
This table summarizes MTMR12 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 6. The strongest signals are observed in LIHC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for MTMR12. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MTMR12 shows lower tumor expression in BRCA, KICH and LUAD and higher tumor expression in LIHC, CHOL and COAD. The LIHC box plot shows higher MTMR12 RNA expression in tumor versus normal tissue (log2 FC = +0.590, t-test p < 0.001).
This table shows molecular features associated with MTMR12 in patient tissues and cancer cell lines. In patient samples, MTMR12 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, MTMR12 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and BLOOD_Lymphoma.
